Skip to main content
. 2017 Sep 6;19(10):830–841. doi: 10.1016/j.neo.2017.08.002

Figure 1.

Figure 1

SCH900776 or Chk1 siRNA mediated sensitization of HCT116 cells to LA-12/cisplatin-induced apoptosis. (A) Percentage of annexin V+/PI− (flow cytometry) HCT116 wt cells and (B) cleavage (cl.) of PARP, caspase-9, level of phosphorylated (Ser139) H2AX (γ-H2AX), phosphorylated (Ser296), and total Chk1 (Western blotting) following pretreatment (2 hours) with SCH900776 (SCH, 3 μM) and subsequent treatment (48 hours) with LA-12 (0.75 μM) or cisplatin (CDDP, 20 μM) in the absence (DMSO) or presence of z-VAD-fmk (10 μM). (C) Cleavage of PARP, caspase-9, caspase-3, level of γ-H2AX and Chk1 (Western blotting), and (D) cleavage of caspase-3 (flow cytometry) in HCT116 wt cells transfected (24 hours) with control or Chk1 siRNA, pretreated (2 hours) with SCH900776 (SCH, 3 μM) and subsequently treated (48 hours) with LA-12 (0.75 μM) or cisplatin (CDDP, 20 μM). Results are means ± SEM or representatives of three independent experiments. Statistical significance: P < .05, * versus control, ‡ versus SCH, Ο versus LA-12 or CDDP and Δ for with versus without z-VAD-fmk or control versus Chk1 siRNA.